BioSpace News Archive

Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.

March 6, 2023
·
24 min read
Business

BPGbio Announces Appointments to its Leadership Team to Accelerate Research and Commercialization

After acquiring substantially all assets of BERG, LLC at the beginning of 2023, BPGbio, Inc, a leading AI-powered biopharma with a mission to reimagine biology for humanity, announced today the appointment of four key executives.

March 6, 2023
·
4 min read
Pharm Country

Corentec to Showcase Innovative Solutions at American Academy of Orthopedic Surgeons 2023 Conference

Corentec, a forward-thinking medical device company focused on developing solutions for the orthopedic market, will be showcasing its latest products at the American Academy of Orthopedic Surgeons 2023 Conference from March 7 to March 11, 2023, in the Venetian Expo booth # 5027.

March 6, 2023
·
2 min read
Zevra Therapeutics to Present at 35th Annual Roth Conference

Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.

March 6, 2023
·
3 min read
Genetown

Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

Sensei Biotherapeutics, Inc. today announced that Company management will present at Oppenheimer’s 33rd Annual Healthcare Conference.

March 6, 2023
·
1 min read
Business

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

March 6, 2023
·
13 min read
Genetown

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACRRelay Therapeutics to host conference call following AACR presentation

Relay Therapeutics, Inc. today announced that initial clinical data from the ReDiscover trial for RLY-2608 have been selected for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.

March 6, 2023
·
5 min read
Business

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

Helius Medical Technologies, Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, after the market closes.

March 6, 2023
·
2 min read
Biotech Bay

Invitae’s PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California.

March 6, 2023
·
3 min read
Drug Development

Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

March 6, 2023
·
8 min read